Charts do shout, page-46

First 46 Last

Share
Profile

Follow
Chartsshout

520 Posts.

16

29/03/18

10:17

Post #: 32110108
Share
Originally posted by Chartsshout ↑

That is half year revenue.

The Mayne Pharma Group Ltd (ASX: MYX) share price is heading in the right direction again during trade on Friday following the release of its half-year results.
At one stage its shares were up as much as 11.5% to 78 cents. They have since given back some of these gains and sit 6.5% higher at 74.5 cents at the time of writing.
Here are key takeaways from the half-year release:

Half-year revenue fell 17% on the prior corresponding period to $243.3 million.

Generic drugs sales were down 19% to $180.9 million.

Adjusted earnings before interest, tax, depreciation, and amortisation (EBITDA) down 36% to $70.2 million. Reported EBITDA down 82% to $23 million.

Reported net loss after tax of $174.2 million.

Positive operating cash flow of $48 million.

Outlook: Stronger second-half expected due to a stabilising generic drugs market and new product launches.

Although on the face of it this looks like a bit of a disaster from Mayne Pharma, I do think there are several positives that could give shareholders reason to be optimistic on the future.
The first one is of course the stabilising generic drugs market. According to research by Barclays, the generic drugs market has suffered from price deflation of 13% year-on-year as of the end of December. But month-on-month prices have inflated 3%. This could arguably be a sign that the worst is now over for the company.
Another reason to be a little more optimistic is the company’s improved performance in the second-quarter of the first-half. Sales in the second-quarter from the company’s key Generic Products Division (GPD) rose 30% on the first-quarter. Pleasingly, this momentum has carried over into January, with GPD sales up 13% on the average monthly sales generated during the second-quarter.
Also, it is worth noting that the reported net loss after tax of $174.2 million was driven largely by asset impairments and negative impacts from U.S. tax reforms. The company made a $184 million non-cash (pre-tax) charge of $184 million on intangible assets related to the acquired Teva portfolio. And a one-off charge to income tax expense of $14 million was made to reflect the restatement of deferred tax assets and liabilities.

The reason it still went up on massive volume on that day apart from future prospects re new generic drugs to be launched etc etc.
are

Positive operating cash flow of $48 million.

Outlook: Stronger second-half expected due to a stabilising generic drugs market and new product launches.

Another reason to be a little more optimistic is the company’s improved performance in the second-quarter of the first-half.

Expand

Adding more at 75.
People got to remember that for Dec17 first half MYX had a free cash flow of 48 million which is likely to be above 100 million for full year.
So shorts got to be hanged here
for shorting it.
I won't give them an inch as a long term investor.
IMHO
DYOR
Last edited by Chartsshout: 29/03/18

MYX Price at posting: 74.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SNT

Syntara shows encouraging first signals it can impact the path to Parkinson's

Australia's resources and energy exports remain strong, despite Middle East crisis

Expert Exchange: David Sokulsky on AI trade, chip stocks, and where to invest now

LISTEN: HotCopper Wire Podcast #052 – Finger lickin' not so good

DBO

Diablo: Horn Silver acquisition approved, maiden Star Range drilling set to commence

First 46 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last $2.90		Change 0.110(3.94%)		Mkt cap ! $226.6M

Open	High	Low	Volume
$2.81	$2.92	$2.79	228.5K

Buyers (Bids)

Vol.	Price($)
1000	$2.84

Sellers (Offers)

Price($)	Vol.
$2.88	1

Last trade - 16.12pm 07/07/2026 (20 minute delay)

MYX (ASX) Chart

Charts do shout, page-46

Syntara shows encouraging first signals it can impact the path to Parkinson's

Australia's resources and energy exports remain strong, despite Middle East crisis

Expert Exchange: David Sokulsky on AI trade, chip stocks, and where to invest now

LISTEN: HotCopper Wire Podcast #052 – Finger lickin' not so good

Diablo: Horn Silver acquisition approved, maiden Star Range drilling set to commence

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Charts do shout, page-46

Top Stories

Syntara shows encouraging first signals it can impact the path to Parkinson's

Australia's resources and energy exports remain strong, despite Middle East crisis

Expert Exchange: David Sokulsky on AI trade, chip stocks, and where to invest now

LISTEN: HotCopper Wire Podcast #052 – Finger lickin' not so good

Diablo: Horn Silver acquisition approved, maiden Star Range drilling set to commence

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News